STUDY OBJECTIVES: We analyzed data from a community-based cancer database over a 26-year period in order to characterize clinicopathologic differences between black and white patients with lung cancer, and to identify relevant temporal trends in incidence and survival. DESIGN, SETTING, AND PATIENTS: Data on demographics, stage, histology, and survival were obtained on all black and white patients with primary bronchogenic carcinoma registered in the community-based metropolitan Detroit Surveillance, Epidemiology, and End Results database from 1973 to 1998. RESULTS: Of 48,318 eligible patients, 23% were black. Lung cancer incidence rates decreased for men of both races from 1985 to 1998, with a greater decline occurring in black men (p < 0.0001). Although incidence rates declined over time for men of both races < 50 years of age, this decrease was greater in white men, resulting in an increase in the racial differential in younger men. Temporal trends in incidence rates were similar for women of both races. The incidence of distant-stage disease was higher among blacks throughout the study period. The incidence of local-stage disease decreased for both races, though this decline was greater in blacks. A significant racial difference in 2-year and 5-year survival rates developed during the study period, due to a distinct lack of improvement in black patients. In a multivariate model, the relative risks of death for black patients, relative to white patients, were 1.24 (p < 0.0001) for local stage, 1.14 (p < 0.0001) for regional stage, and 1.03 (p = 0.045) for distant stage. CONCLUSION: Significant racial differences exist in the incidence and survival rates for lung cancer in metropolitan Detroit. Since 1973, several disturbing trends have developed, particularly with regard to the lack of improvement in overall survival in black patients. Further study is required to determine the factors responsible for these temporal trends.
STUDY OBJECTIVES: We analyzed data from a community-based cancer database over a 26-year period in order to characterize clinicopathologic differences between black and white patients with lung cancer, and to identify relevant temporal trends in incidence and survival. DESIGN, SETTING, AND PATIENTS: Data on demographics, stage, histology, and survival were obtained on all black and white patients with primary bronchogenic carcinoma registered in the community-based metropolitan Detroit Surveillance, Epidemiology, and End Results database from 1973 to 1998. RESULTS: Of 48,318 eligible patients, 23% were black. Lung cancer incidence rates decreased for men of both races from 1985 to 1998, with a greater decline occurring in black men (p < 0.0001). Although incidence rates declined over time for men of both races < 50 years of age, this decrease was greater in white men, resulting in an increase in the racial differential in younger men. Temporal trends in incidence rates were similar for women of both races. The incidence of distant-stage disease was higher among blacks throughout the study period. The incidence of local-stage disease decreased for both races, though this decline was greater in blacks. A significant racial difference in 2-year and 5-year survival rates developed during the study period, due to a distinct lack of improvement in black patients. In a multivariate model, the relative risks of death for black patients, relative to white patients, were 1.24 (p < 0.0001) for local stage, 1.14 (p < 0.0001) for regional stage, and 1.03 (p = 0.045) for distant stage. CONCLUSION: Significant racial differences exist in the incidence and survival rates for lung cancer in metropolitan Detroit. Since 1973, several disturbing trends have developed, particularly with regard to the lack of improvement in overall survival in black patients. Further study is required to determine the factors responsible for these temporal trends.
Authors: Janis Campbell; Krupa Gandhi; Anne Pate; Amanda Janitz; Amber Anderson; Robin Kinnard; Kai Ding Journal: J Okla State Med Assoc Date: 2016 Jul-Aug
Authors: Sirisha Jonnalagadda; Jenny J Lin; Judith E Nelson; Charles A Powell; John Salazar-Schicchi; Andrew R Berman; Steven M Keller; Cardinale B Smith; Linda Lurslurchachai; Ethan A Halm; Howard Leventhal; Juan P Wisnivesky Journal: Chest Date: 2012-11 Impact factor: 9.410
Authors: M A Phelps; T E Stinchcombe; J S Blachly; W Zhao; L J Schaaf; S L Starrett; L Wei; M Poi; D Wang; A Papp; J Aimiuwu; Y Gao; J Li; G A Otterson; W J Hicks; M A Socinski; M A Villalona-Calero Journal: Clin Pharmacol Ther Date: 2014-04-29 Impact factor: 6.875
Authors: Kyle M Walsh; Ivan P Gorlov; Helen M Hansen; Xifeng Wu; Margaret R Spitz; Huifeng Zhang; Emily Y Lu; Angela S Wenzlaff; Jennette D Sison; Chongjuan Wei; Stacy M Lloyd; Wei Chen; Marsha L Frazier; Michael F Seldin; Laura J Bierut; Paige M Bracci; Margaret R Wrensch; Ann G Schwartz; John K Wiencke; Christopher I Amos Journal: Cancer Epidemiol Biomarkers Prev Date: 2012-12-05 Impact factor: 4.254
Authors: Keith M Wille; Kathy F Harrington; Joao A deAndrade; Sonia Vishin; Robert A Oster; Richard A Kaslow Journal: J Heart Lung Transplant Date: 2013-04-09 Impact factor: 10.247